Elizabeth Davis - August 17, 2016
Americans, get ready for sticker shock at the pharmacy.
In 2017, the nation’s largest insurance companies will likely exclude up to 154 different drugs from coverage. If you’re taking one of these prescriptions, your co-pay is about to go way, way up.
Last year, popular drugs including Viagra and Qsymia were dropped by major insurance plans for 2016. The trend continues this year. Almost 50 popular brand-name and generic drugs will likely no longer be covered by one of the nation’s largest prescription insurance providers. See More
Dr. Sharon Orrange - June 07, 2016
Insulin: legal, widely used, and transforms lives. But there are risks—soon you’ll see why we try to spare our type II diabetics from having to start insulin. Using oral medications to their maximum dose and incorporating diet and lifestyle changes is the way to go before resorting to insulin.
Of course, tight blood sugar control is the goal for reducing diabetes related complications (kidney disease, eye disease, neuropathy) but insulin remains one of the most challenging aspects of diabetes management given the risks. See More
The GoodRx Pharmacist - October 23, 2015
The other recent insulin approvals are what I like to call spin-off insulin products. For example, Toujeo has the same type of insulin as Lantus (insulin glargine), but is more concentrated. Humalog U-200 is the same exact product as Humalog U-100 (insulin lispro), but once again, more concentrated. See More
Dr. Sharon Orrange - October 06, 2015
More than 29 million Americans have diabetes. That’s more than 10% of the US—and that number continues to rise. More than 1.7 million adults were diagnosed with diabetes in 2012 alone.
Fortunately, several new medications for diabetes have recently been approved—Toujeo (a new insulin product), Synjardy (a new combination of empagliflozin/metformin) and others. These new drugs provide several benefits such as fewer side effects or foolproof self-dosing with an insulin pen. See More
The GoodRx Pharmacist - August 18, 2015
Early in 2015 the FDA approved the first concentrated long-acting insulin known as Toujeo (insulin glargine), and it’s now available in pharmacies.
While Toujeo is the first of its kind, the key word is “concentrated.” It actually contains the same active ingredient (insulin glargine) as Lantus—which is currently the #1 prescribed insulin in the US.
The GoodRx Pharmacist - May 05, 2015
Did you read our blog on insulin vials and think to yourself, does this apply to my insulin pens too? If so, this post is for you!
With so many different insulin and insulin-like products out there these days it can be hard keep track of how long each of these pens stays good.
Depending on your dose, you may still have insulin left in your pen at the manufacturer-recommended time to throw it away. If this sounds like a familiar situation, know that it is important to throw away your pen regardless of whether you have any leftover. See More
The GoodRx Pharmacist - March 26, 2015
On February 25, 2015, the FDA approved Toujeo—a long-acting insulin indicated to improve sugar control in adults with type 1 and type 2 diabetes.
When will Toujeo be available?
According to the manufacturer, Sanofi-Aventis, Toujeo will be available at the beginning of the second quarter in 2015.
What is long-acting insulin?
Long-acting insulin can also be referred to as basal insulin. Long-acting insulin lowers blood sugar levels slowly and evenly for up to 24 hours. See More